Efficacy of a Probiotic and Herbal Supplement in Models of Lung Inflammation.

Wenger, Nancy M; Qiao, Luhua; Nicola, Teodora; Nizami, Zoha; Xu, Xin; Willis, Kent A; Ambalavanan, Namasivayam; Gaggar, Amit; Lal, Charitharth Vivek.

Afiliação

Wenger NM; ResBiotic Nutrition Inc., Birmingham, AL 35203, USA.
Qiao L; Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Nicola T; Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Nizami Z; Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Xu X; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Willis KA; Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Ambalavanan N; Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Gaggar A; Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Lal CV; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

Microorganisms ; 10(11)2022 Oct 28.

Article em En | MEDLINE | ID: mdl-36363728

ABSTRACT

BACKGROUND:

Gut microbiome dysbiosis is associated with lung disease through the gut-lung axis. Abundant proteobacteria increase MMP-9 and contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic lung disease. We sought to determine if a scientifically formulated probiotic and herbal supplement could attenuate neutrophilic inflammation and improve lung structure and function in models of lung inflammation.

For in vitro experiments, epithelial cells exposed to proteobacteria were treated with resB-a blend of three probiotic Lactobacillus strains and turmeric, holy basil, and vasaka herbal extracts. For in vivo experimentation, mice exposed to pulmonary proteobacteria-derived lipopolysaccharide were treated by gavage with resB.

In vitro, the bacterial and herbal components of resB decreased activity of the MMP-9 pathway. Mice exposed to LPS and pre- and post-treated with resB had decreased neutrophil recruitment and inflammatory biomarkers in bronchoalveolar lavage fluid, serum, and lung tissue compared to untreated mice.